Damora Therapeutics, Inc. reports news around its biotechnology pipeline for mutCALR-driven blood disorders, financial results, and corporate development following the completed acquisition that added DMR-001, DMR-002, and DMR-003. Company updates also describe governance changes, board and executive appointments, and equity compensation actions under Nasdaq inducement-grant rules.
Recurring Damora news centers on hematologic disorders, myeloproliferative neoplasms, research and development progress, capital resources, and public-company governance matters tied to its Nasdaq-listed common stock.
Damora Therapeutics (NASDAQ: DMRA) appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and added biotech leaders Cameron Turtle and Mike Landsittel to the Board. Peter Harwin was named Chairman. Management changes accompany a focus on advancing lead program DMR-001 and portfolio development.
Damora Therapeutics (NASDAQ: DMRA) reported full-year 2025 results and corporate milestones on March 19, 2026. The company completed acquisition of mutCALR-focused assets, raised gross proceeds of approximately $285 million (private) and $316 million (public), and holds about $535 million in cash as of February 28, 2026. Damora expects an IND/CTA for lead candidate DMR-001 by mid-2026 and two proof-of-concept datasets beginning mid-2027.
2025 results include R&D expense of $26.9M, G&A of $9.7M, and a net loss of $209.8M largely driven by a $174.3M acquired in-process R&D charge.